Samelisant

Samelisant (INNTooltip International Nonproprietary Name; developmental code name SUVN-G3031) is an experimental wakefulness-promoting agent acting as a selective histamine H₃ receptor inverse agonist which is under development for the treatment of narcolepsy.^[1][2][3][4] It was also under development for the treatment of cognition disorders and Parkinson's disease, but no recent development has been reported for these indications.^[1][3] As of June 2024, samelisant is in phase 2 clinical trials for the treatment of narcolepsy.^[1][5]

Samelisant

Clinical data
Other names	SUVN-G3031
Drug class	Histamine H3 receptor inverse agonist; Wakefulness-promoting agent
Pharmacokinetic data
Elimination half-life	23-34 hours
Identifiers
IUPAC name N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide
CAS Number	1394808-82-2
PubChem CID	60151477
IUPHAR/BPS	10232
DrugBank	DB14835
ChemSpider	64854818
UNII	65V47O9NOP
ChEMBL	ChEMBL4297328
Chemical and physical data
Formula	C21H31N3O3
Molar mass	373.497 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4
InChI InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25) Key:LNXDUSQEXVQFGP-UHFFFAOYSA-N

See also

• Pitolisant